Themis Medicare Ltd
Themis Medicare Ltd Q3 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Themis Medicare Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY26 net revenue: Rs. Q3 FY26 Financials (Page 8 & 7): - EBITDA: ₹9.80 Cr, up 14.9% YoY - EBITDA Margin: 10.87%, improved by 178 basis points YoY - PAT: ₹10.09 Cr, up 1843.7% YoY - PAT Margin: 11.20%, up 1065 basis points YoY - Year-on-Year Changes (9M FY26, Page 9): - EBITDA: -₹3.37 Cr vs.
From Themis Medicare Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 net revenue: Rs. 90.13 Cr, a 3.9% decline year-on-year from Rs. 93.81 Cr in Q3 FY25 (Page 8).
- 9M FY26 net revenue: Rs. 265.71 Cr, a 20.4% decline year-on-year from Rs. 333.81 Cr in 9M FY25 (Page 9).
- Q3 FY26: API business grew more than double YoY, partially offset by softness in formulations segment (Page 5).
- Sales mix shifting towards higher API revenue share (Page 8).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation does not explicitly detail specific capex amounts or individual projects related to capacity expansion or new plants on the pages provided.
- Page 14 lists current manufacturing facilities and their capacities:
- Haridwar: Formulations (520 mn Tablets, 9 mn Ointment Tubes, 36 mn Ampoules, 12 mn Vials, 6 mn Pre-filled Syringes)
- Hyderabad and Vapi: Synthetic APIs with capacities of 120 MT and 191 MT respectively.
- Page 15 mentions continued R&D investment (~Rs. 13-14 Cr annually) but no direct capex or expansion timelines.
- Page 18 hints at strategic expansion plans:
- Phase I (0-3 years): Focus on new Rest of World markets (CIS, Latin America, GCC)
- Phase II (3-5 years): Enter regulated markets (EU, USA)
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q3 FY26)
Quarterly Revenue (Q3FY26):** ₹127.51 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q3 FY26 investor presentation — and how it ranks aga
- Shree Ganesh Remedies Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹21.11 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation — and how it rank
- Anuh Pharma Ltd (Q3 FY26)
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) . Key investor presentation takeaw
- Bharat Parenterals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9). Key investor presentation takeaways from Bharat
Frequently Asked Questions
What were Themis Medicare Ltd Q3 FY26 results?
Q3 FY26 net revenue: Rs. Q3 FY26 Financials (Page 8 & 7): - EBITDA: ₹9.80 Cr, up 14.9% YoY - EBITDA Margin: 10.87%, improved by 178 basis points YoY - PAT: ₹10.09 Cr, up 1843.7% YoY - PAT Margin: 11.20%, up 1065 basis points YoY - Year-on-Year Changes (9M FY26, Page 9): - EBITDA: -₹3.37 Cr vs.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The presentation does not explicitly detail specific capex amounts or individual projects related to capacity expansion or new plants on the pages provided. - Page 14 lists current manufacturing facilities and their capacities: - Haridwar: Formulations (520 mn Tablets, 9 mn Ointment Tubes, 36 mn Ampoules, 12 mn Vials, 6 mn Pre-filled Syringes) - Hyderabad and Vapi: Synthetic APIs with capacities of 120 MT and 191 MT respectively. - Page 15 mentions continued R&D investment (~Rs.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.